Please use this identifier to cite or link to this item:
DC FieldValueLanguage
dc.contributor.authorEl Masri, Jaden_US
dc.contributor.authorEl Ayoubi, Lemir Majeden_US
dc.contributor.authorZreika, Bachiren_US
dc.contributor.authorAdhami, Fouaden_US
dc.contributor.authorEl Masri, Dialaen_US
dc.contributor.authorEl Hage, Saiden_US
dc.contributor.authorAbou-Jaoudé, Marounen_US
dc.description.abstractBackground Liver transplant (LT) is the second most common transplant intervention. The rate of acute cellular rejection (ACR) is 15–25% after LT, while being higher in chronic rejection (CR). Clinical trials had a major role in getting more potent and selective immunosuppressive medications. Our study plays an important role by evaluating and tracking clinical trials related to liver transplant rejection, focusing on interventional therapeutic trials. Methods On October 28, we searched for interventional clinical trials related to liver transplant rejection. A total of 27 clinical trials included in this study. Characteristics on each trial were collected, and availability of linked publications was searched using Medline/PubMed and Embase/Scopus. Content of publications was reviewed and main findings were summarized. Results Majority of trials were completed (15 out of 27). Eleven trials had between 11 and 50 participants, and 10 had above 100. The study duration was between 1 and 4 years for the majority of trials (16 trials), with an average of 3.77 years. Most of the trials were done in Europe/UK/Russia (n = 12). The results were provided in 9 trials but published in 4, showing the possible tolerogenic efficacy of MSC in liver transplantation, increased success of immunosuppression (IS) withdrawal after sirolimus addition, efficacy of Alemtuzumab, normal graft function and stability within 1 year of immunosuppression withdrawal. Conclusion This study revealed a low number of trials, lack of variety in location and low publishing rates. The focus of trials was mainly towards side effects and safety of immunosuppressants, and their withdrawal. These trials reached results that must be built on to reach definitive guidelines and treatment strategies. This highlights the need for better management of human and financial resources, in order to reach new and more effective therapeutic strategies, leading to the decrease in rate of LTR.en_US
dc.subjectClinical trialsen_US
dc.subjectTransplant rejectionen_US
dc.titleCurrent state of clinical trials regarding liver transplant rejectionen_US
dc.typeJournal Articleen_US
dc.contributor.affiliationFaculty of Medicineen_US
dc.relation.ispartoftextTransplant Immunologyen_US
Appears in Collections:Faculty of Medicine
Show simple item record


checked on Aug 13, 2022

Record view(s)

checked on Aug 19, 2022

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.